Skip to main content

Table 4 Per protocol analysis of ultrasound examination

From: Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial

Tocotrienols group (n = 30)

Changes at completion of the study

Baseline

Negative

Mild

Moderate

Severe

Mild (n = 22)

13/22

9/22

0/22

0/22

73.3%

59.1%

40.9%

0.0%

0.0%

Moderate (n = 6)

2/6

4/6

0/6

0/6

20.0%

33.3%

66.7%

0.0%

0.0%

Severe (n = 2)

0/2

1/2

0/2

1/2

6.7%

0.0%

50.0%

0.0%

50.0%

  TOTAL

15/30

14/30

0/30

1/30

 

50.0%

46.7%

0.0%

3.3%

Placebo group (n = 34)

Changes at completion of the study

Baseline

Negative

Mild

Moderate

Severe

Mild (n = 27)

8/27

17/27

2/27

0/27

79.4%

29.6%

63.0

7.4%

0.0%

Moderate (n = 6)

0/6

5/6

1/6

0/6

17.6%

0.0%

83.3%

16.7%

0.0%

Severe (n = 1)

0/1

0/1

1/1

0/1

2.9%

0.0%

0.0%

100.0%

0.0%

  TOTAL

8/34

22/34

4/34

0/34

 

23.5%

64.7%

11.8%

0.0%

Tocotrienols vs Placebo

Chi Sq = 4.851

P = 0.014

  
  1. Details of the clinical evaluation of subjects at baseline and relative changes after 1 year of treatment.
  2. [Helmert-Pearson’s Chi Square; Numbers’09, GraphPad].